(Q40551019)

21 September 2017

title

Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides (English)

1 reference

21 September 2017

Kamal Datta

1

1 reference

21 September 2017

Preeti Shah

2

1 reference

21 September 2017

Tapasya Srivastava

3

1 reference

21 September 2017

Srinivas G Mathur

4

1 reference

21 September 2017

Parthaprasad Chattopadhyay

5

1 reference

21 September 2017

Subrata Sinha

6

1 reference

21 September 2017

language of work or name

1 reference

1 August 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

11

1 reference

21 September 2017

issue

8

1 reference

21 September 2017

page(s)

525-531

1 reference

Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Expression of p53 and prognosis in children with malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53 protein overexpression and chemosensitivity in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Rescuing the function of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Cell cycle control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Mutant p53 protein associated with chemosensitivity in breast cancer specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Cisplatin (CDDP)-induced radiation resistance is not associated with CDDP resistance in 86HG39 and A172 malignant glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53 and brain tumors: from gene mutations to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Contribution of caspase-3 differs by p53 status in apoptosis induced by X-irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

p53-dependent apoptosis pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Regulation of the G2/M transition by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Chemosensitivity of prostatic tumour cell lines under conditions of G2 block abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2/M checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

Ondansetron for intractable vertigo complicating acute brainstem disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

p53-degradation by HPV-16 E6 preferentially affects the removal of cyclobutane pyrimidine dimers from non-transcribed strand and sensitizes mammary epithelial cells to UV-irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

Role of p53 in drug resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700724

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700724

1 reference

Dimensions Publication ID

21 September 2017

1027335940

0 references

1 reference